Jan 16, 2025
6 minutes read
Drug safety has been the backbone of the pharmaceutical industry. It is the systematic process and the science of monitoring the safety of medications, a need that has become increasingly critical in today's regulatory landscape and heightened focus on patient safety. Despite this emphasis, one might think that the industry is flooded with professionals in this vital area. In truth, however, there seem to be quite a few vacancies, both in the industry, along with academia, for workers who can monitor the safety of drugs. This is not a problem confined to the United States; other countries that stand out in the global pharmaceutical landscape have similar problems.This blog will serve as a source of information for individuals who might be considering the career path of pharmacovigilance. If you are a student, a healthcare provider, or someone else already working in a field related to pharmacovigilance and are contemplating a switch, this is the place to come for information. And if you’re just browsing and trying to understand what pharmacovigilance is and what kinds of careers it offers, you’re welcome here, too.
An expanding area of importance, pharmacovigilance is responsible for ensuring the safe use of drugs and protecting public health. It is an area where much pharmaceutical innovation and drug development are apparent. Coupled with this intense activity is the need to manage adverse drug reactions (ADRs) through effective monitoring of the safety parameters. Pharmacovigilance professionals are part of post-marketing surveillance, regulatory compliance, and risk management. They work under the tight scrutiny of the standards set by the FDA, EMA, and WHO. Automated adverse drug reaction reporting and signal detection in new technologies like AI and machine learning give pharmacovigilance a bright, efficient future. Indeed, it may be at the forefront of offering a dynamically safer drug experience for humans.
The FDA sanctioned 50 new molecular entities (NMEs) for the year 2024, which is pretty much in line with the uptick in the number of approvals in this area for the last few years2. This steady stream of approvals underlines the increasing armamentarium of treatment options and yet again raises the critical need for good pharmacovigilance to safeguard patients from emerging safety signals. The more therapies that come to market, the more necessary strong oversight becomes to protect both patients and the appearance of integrity in the regulatory system.
The size of the global market for pharmacovigilance is anticipated to reach $11.78 billion by 2030, growing at a compound annual growth rate of 6.8% between 2024 and 2030, according to a report from Grand View Research8. The growth rate for biopharma is expected to be faster because many new therapies are being developed and studied. In tandem with this growth, there is an increased incidence of adverse drug reactions. For example, serious ADRs reported to the FDA increased from around 35,000 in 2001 to nearly 180,000 in 20109. ADRs are estimated by some to cause around 197,000 deaths every year in the EU alone, contributing to an economic burden of about €79 billion7.These figures are over a decade old. As one can see from these impressive and in some cases, scary numbers, pharmacovigilance is an urgent and profitable field in which to work. Both major and emerging market CROs should thus be looking to capitalize on this strong demand.
Vaccine safety has come back into greater focus, and pharmacovigilance has stepped into the global spotlight, especially after the pandemic. Public debates on the benefits and risks of vaccines have taken center stage and, in some cases, have even overshadowed the exceptional real-world evidence we are generating in favor of COVID-19 vaccines. Maintaining public trust in health care requires that we be vigilant, that we communicate clearly and honestly, and that we remember how quickly the field of vaccine safety can evolve.
The Thalidomide Incident: In the 1960s, thalidomide was the medication of choice to assist pregnant women in dealing with morning sickness; countless infants who were carried to term paid the price in the form of profound birth defects associated with their mothers' use of the drug. The catastrophe spurred a shift in the way drugs were viewed and demanded calls for much more rigorous drug safety assessment and postmarket monitoring11.
Monitoring COVID-19 Vaccines:
The frameworks for pharmacovigilance were at the very forefront of identifying very rare side effects related to myocarditis among COVID-19 vaccines. This type of early signal allows healthcare authorities to adopt necessary precautions without disrupting public trust in vaccination programs12.
For the majority of pathways into pharmacovigilance, these degrees are most common:
Technical Expertise
Analytical and Problem-Solving Skills
Regulatory Knowledge
Communication Skills
Adaptability
Drug Safety Associate
Accountability: The first step in processing serious adverse drug reactions. It is an added responsibility to ensure a higher degree of accuracy for the analysis of adverse drug reactions to drugs and drug combinations. Compensation per year: $40,000 - $60,000.
Pharmacovigilance Officer
Ensuring that the operations are within regulatory guidelines and preparing safety reports for submission to any authority. Compensation per year: $50,000 to $70,000.
Pharmacovigilance Scientist Job Title: Signal Analyst.
Signal Detection Specialist Position: Uses data analytics to discern patterns or safety problems in reported negative reactions. Annual salary: $70,000 to $90,000
Risk Management Lead
Function: Crafts and executes plans to lessen the chance of negative outcomes linked to products that are currently on the market. Annual Salary:$100,000 to $150,000.
Director of Pharmacovigilance
Function: Ensures that an organization's worldwide pharmacovigilance activities comply with international laws and regulations and sound practices. Annual Salary: $150,000 to $200,000.
Ensuring drug safety through pharmacovigilance is a complex task. Even though it is a vital component of drug safety, it suffers from many drawbacks and faces multiple challenges:
Impacting patient safety and public health goes directly with a career in pharmacovigilance. This professional field continues to grow and innovate, and it holds great promise for stability and career growth. Fill that void and seek a move into this space through an avenue that brings you the most fulfillment. Resources like ACMALifeSciences.org, pursue relevant certifications, expand your skill set, and connect with industry experts to start your journey. Why does this all matter? Because your next step could significantly impact something that really counts, helping ensure that patients are safe.
U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). January 9, 2025. https://www.fda.gov/drugs/surveillance/fda-adverse-event-reporting-system-faers
U.S. Food and Drug Administration. Novel Drug Approvals for 2024. January 9, 2025. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
ACMA. BCMAS Certification Program. January 9, 2025. https://medicalaffairsspecialist.org/
World Health Organization (WHO). Pharmacovigilance Guidelines. January 9, 2025.https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/
Drug Information Association (DIA). DIA Global: Drug Safety Programs. January 9, 2025. https://www.diaglobal.org/en/course-listing/elearning/2023/02/introduction-to-drug-safety
MarketWatch. Pharmacovigilance Market Trends 2023–2030. January 9, 2025. https://www.marketwatch.com/press-release/pharmacovigilance-and-drug-safety-software-strategic-market-report-2024-2030-rising-focus-on-patient-safety-and-adverse-event-reporting-bolster-growth-researchandmarkets-com-6eec6885
Grand View Research. Pharmacovigilance Industry Analysis. January 9, 2025. https://www.grandviewresearch.com/industry-analysis/pharmacovigilance-industry
Institute for Safe Medication Practices (ISMP). QuarterWatch: Monitoring FDA MedWatch Reports. January 9, 2025. https://www.ismp.org/sites/default/files/attachments/2018-01/2016Q4_1.pdf
European Medicines Agency (EMA). Pharmacovigilance System: Questions & Answers. January 9, 2025.https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/pharmacovigilance-system-questions-answers
PMC. Thalidomide: A Tragic Case Study in Drug Safety. January 9, 2025.https://pmc.ncbi.nlm.nih.gov/articles/PMC3573415/
Centers for Disease Control and Prevention (CDC). COVID-19 Vaccine Safety Monitoring. January 9, 2025.https://www.cdc.gov/vaccine-safety/vaccines/covid-19.html